- Home
- FFA vs CAPR Comparison
FFA vs CAPR Comparison
Compare FFA & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFA
- CAPR
- Stock Information
- Founded
- FFA 2004
- CAPR 2005
- Country
- FFA United States
- CAPR United States
- Employees
- FFA N/A
- CAPR N/A
- Industry
- FFA Investment Managers
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FFA Finance
- CAPR Health Care
- Exchange
- FFA Nasdaq
- CAPR Nasdaq
- Market Cap
- FFA 400.0M
- CAPR 392.8M
- IPO Year
- FFA N/A
- CAPR N/A
- Fundamental
- Price
- FFA $18.11
- CAPR $11.25
- Analyst Decision
- FFA
- CAPR Strong Buy
- Analyst Count
- FFA 0
- CAPR 7
- Target Price
- FFA N/A
- CAPR $39.29
- AVG Volume (30 Days)
- FFA 26.1K
- CAPR 1.4M
- Earning Date
- FFA 01-01-0001
- CAPR 05-12-2025
- Dividend Yield
- FFA 6.72%
- CAPR N/A
- EPS Growth
- FFA N/A
- CAPR N/A
- EPS
- FFA N/A
- CAPR N/A
- Revenue
- FFA N/A
- CAPR $22,270,465.00
- Revenue This Year
- FFA N/A
- CAPR $78.85
- Revenue Next Year
- FFA N/A
- CAPR $157.99
- P/E Ratio
- FFA N/A
- CAPR N/A
- Revenue Growth
- FFA N/A
- CAPR N/A
- 52 Week Low
- FFA $15.84
- CAPR $3.52
- 52 Week High
- FFA $19.30
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- FFA 42.25
- CAPR 52.49
- Support Level
- FFA $17.84
- CAPR $9.43
- Resistance Level
- FFA $18.48
- CAPR $10.09
- Average True Range (ATR)
- FFA 0.68
- CAPR 0.93
- MACD
- FFA 0.04
- CAPR 0.22
- Stochastic Oscillator
- FFA 68.05
- CAPR 97.82
About FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide a high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.